Allogeneic hematopoietic cell transplantation (alloHCT) for multiple myeloma (MM), with its
underlying graft-versus-tumor capacity, is a potentially curative approach for high-risk …

Many patients with multiple myeloma (MM) eventually relapse even after allogeneic
hematopoietic cell transplantation (alloHCT) for curative intent. Over the past decade …

Autologous stem cell transplantation (autoHCT) is considered standard of care for newly
diagnosed multiple myeloma (MM). Although most patients eventually progress after …

Background Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative
option for multiple myeloma (MM). We analyzed our experience of allo-HCT in MM and …

Despite remarkable progress in survival with the availability of novel agents, an
overwhelming majority of patients with multiple myeloma (MM) have disease that relapses …

Autologous hematopoietic cell transplantation (AHCT) as initial therapy of patients with
multiple myeloma (MM) improves survival. However, data to support this approach for …

Duration of initial disease response remains a strong prognostic factor in multiple myeloma
(MM) particularly for upfront autologous hematopoietic cell transplant (AHCT) recipients. We …

A total of 149 patients with multiple myeloma (MM) who received allogeneic hematopoietic
stem cell transplantation (allo‐HCT) with myeloablative (MAC; n= 38) or reduced‐intensity …

Background: The role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in
the setting of refractory multiple myeloma (MM) is still controversial. Although potentially …

Background: Despite offering an attractive option, the role of allogeneic stem cell
transplantation (alloSCT) for treatment of multiple myeloma (MM) remains unclear. Methods …